Novo Nordisk

News

Shares in Novo Nordisk rose this morning after its highly anticipated first-quarter results revealed better-than-expected uptake of oral Wegovy.

News

Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.

News

Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.

News

Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.

News

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.

News

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.